UNSPSC 51342705: Interferon alfa-2a

This classification denotes an interferon, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 47RRR83SK7. European Medicines Agency schedules Interferon alfa-2a in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12447MIG. As of Q4 2014, INTERFERON ALFA-2A remains the US FDA Preferred Term for this commodity. SMILES: NONE.

UNSPSC 51342705 Interferon alfa-2a is a Commodity code that nominally names a specific pharmaceutical product, but recent state and local procurement activity under this code shows little relevance to interferon alfa-2a itself. Instead, the opportunities posted against this code span a much broader range of pharmaceutical and medical supply categories — naloxone and drug deactivation systems, generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing, direct-to-manufacturer prescription programs, and medical and first aid supplies for emergency response. State and local issuers soliciting under this code include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), municipal purchasing departments (City of Tampa), and multistate cooperative purchasing alliances (Minnesota MMCAP). The scope of work is heterogeneous: some opportunities seek specific pharmaceutical inventory for health initiatives or emergency services; others pursue framework agreements with manufacturers or wholesalers to supply multiple product lines across member jurisdictions; and at least one RFI (Texas) gathers market intelligence on direct contracting models that bypass traditional pharmacy benefit managers and group purchasing organizations.

Geographic activity spans Florida, Texas, Minnesota, and Oregon, with the most structured recent opportunity being the Minnesota MMCAP RFP for generic pharmaceuticals and OTC products (due March 26, 2026) serving multiple state and local facilities across participating jurisdictions and distributed through three authorized wholesalers. The City of Tampa's IFB for medical and first aid supplies for the Fire Department Rescue Division (due March 13, 2026) represents a narrower municipal procurement, estimated at $700,000, designated as a sheltered market opportunity for certified Small Local Business Enterprises with a 5 percent bid discount. Seminole County's IFB for naloxone and drug deactivation systems (due July 26, 2023, though posted in June 2026) seeks annual supply of 1,900 units of naloxone and 800 deactivation systems with quarterly deliveries to a county health facility. The Texas HHS RFI (response deadline April 3, 2026) functions as exploratory market research rather than a binding procurement, gathering vendor capabilities for direct-to-manufacturer prescription fulfillment outside traditional PBM and GPO structures. The code shows material recent activity but no clear concentration among repeat issuing bodies or specific states.